These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 21933609

  • 1. Impact of benazepril on contrast-induced acute kidney injury for patients with mild to moderate renal insufficiency undergoing percutaneous coronary intervention.
    Li XM, Cong HL, Li TT, He LJ, Zhou YJ.
    Chin Med J (Engl); 2011 Jul; 124(14):2101-6. PubMed ID: 21933609
    [Abstract] [Full Text] [Related]

  • 2. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
    Geng W, Fu XH, Gu XS, Wang YB, Wang XC, Li W, Jiang YF, Hao GZ, Fan WZ, Xue L.
    Chin Med J (Engl); 2012 Oct; 125(19):3368-72. PubMed ID: 23044290
    [Abstract] [Full Text] [Related]

  • 3. Comparison of risk factors for contrast-induced acute kidney injury between patients with and without diabetes.
    Pakfetrat M, Nikoo MH, Malekmakan L, Tabande M, Roozbeh J, Ganbar Ali RJ, Khajehdehi P.
    Hemodial Int; 2010 Oct; 14(4):387-92. PubMed ID: 20796046
    [Abstract] [Full Text] [Related]

  • 4. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
    Bainey KR, Rahim S, Etherington K, Rokoss ML, Natarajan MK, Velianou JL, Brons S, Mehta SR, CAPTAIN Investigators.
    Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
    [Abstract] [Full Text] [Related]

  • 5. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
    Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P.
    N Engl J Med; 1996 Apr 11; 334(15):939-45. PubMed ID: 8596594
    [Abstract] [Full Text] [Related]

  • 6. Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention.
    Andò G, de Gregorio C, Morabito G, Trio O, Saporito F, Oreto G.
    Circ Cardiovasc Interv; 2014 Aug 11; 7(4):465-72. PubMed ID: 25027519
    [Abstract] [Full Text] [Related]

  • 7. New strategy of α- and γ-tocopherol to prevent contrast-induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures.
    Tasanarong A, Vohakiat A, Hutayanon P, Piyayotai D.
    Nephrol Dial Transplant; 2013 Feb 11; 28(2):337-44. PubMed ID: 23314316
    [Abstract] [Full Text] [Related]

  • 8. Incidence of contrast-induced acute kidney injury associated with diagnostic or interventional coronary angiography.
    Morabito S, Pistolesi V, Benedetti G, Di Roma A, Colantonio R, Mancone M, Sardella G, Cibelli L, Ambrosino M, Polistena F, Pierucci A.
    J Nephrol; 2012 Feb 11; 25(6):1098-107. PubMed ID: 22383347
    [Abstract] [Full Text] [Related]

  • 9. A randomized trial of saline hydration to prevent contrast-induced nephropathy in patients on regular captopril or furosemide therapy undergoing percutaneous coronary intervention.
    Shemirani H, Pourrmoghaddas M.
    Saudi J Kidney Dis Transpl; 2012 Mar 11; 23(2):280-5. PubMed ID: 22382219
    [Abstract] [Full Text] [Related]

  • 10. Risk stratification according to the type of impaired renal function in patients with acute myocardial infarction treated with percutaneous coronary intervention.
    Kowalczyk J, Lenarczyk R, Kowalski O, Swiatkowski A, Stabryła-Deska J, Kurek T, Honisz G, Kukulski T, Gasior M, Kalarus Z.
    Kardiol Pol; 2007 Jun 11; 65(6):635-43; discussion 644. PubMed ID: 17629825
    [Abstract] [Full Text] [Related]

  • 11. The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study.
    Rim MY, Ro H, Kang WC, Kim AJ, Park H, Chang JH, Lee HH, Chung W, Jung JY.
    Am J Kidney Dis; 2012 Oct 11; 60(4):576-82. PubMed ID: 22658321
    [Abstract] [Full Text] [Related]

  • 12. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury.
    Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, Golia B, Ricciardelli B, Condorelli G, REMEDIAL II Investigators.
    Circulation; 2011 Sep 13; 124(11):1260-9. PubMed ID: 21844075
    [Abstract] [Full Text] [Related]

  • 13. Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors, and prognosis.
    Maioli M, Toso A, Leoncini M, Gallopin M, Musilli N, Bellandi F.
    Circulation; 2012 Jun 26; 125(25):3099-107. PubMed ID: 22592896
    [Abstract] [Full Text] [Related]

  • 14. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial).
    Lee SW, Kim WJ, Kim YH, Park SW, Park DW, Yun SC, Lee JY, Kang SJ, Lee CW, Lee JH, Choi SW, Seong IW, Suh J, Cho YH, Lee NH, Cheong SS, Yoo SY, Lee BK, Lee SG, Hyon MS, Shin WY, Lee SW, Jang JS, Park SJ.
    Am J Cardiol; 2011 May 15; 107(10):1447-52. PubMed ID: 21420063
    [Abstract] [Full Text] [Related]

  • 15. Preventive effect of statin pretreatment on contrast-induced acute kidney injury in patients undergoing coronary angioplasty: propensity score analysis from a multicenter registry.
    Hoshi T, Sato A, Kakefuda Y, Harunari T, Watabe H, Ojima E, Hiraya D, Abe D, Nishina H, Takeyasu N, Noguchi Y, Aonuma K.
    Int J Cardiol; 2014 Feb 01; 171(2):243-9. PubMed ID: 24393575
    [Abstract] [Full Text] [Related]

  • 16. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan 01; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 17. [The use of recombinant human B-type natriuretic peptide for the protection of cardiac and renal functions in heart failure patients with acute anterior myocardial infarction in peri-operative period of primary percutaneous coronary intervention].
    Zhang J, Fu XH, Fan XN, Jia XW, Gu XS, Li SQ, Jiang YF, Fan WZ, Su JL.
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Nov 01; 22(11):669-73. PubMed ID: 21122202
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome.
    Wang YB, Fu XH, Gu XS, Wang XC, Zhao YJ, Hao GZ, Jiang YF, Fan WZ, Wu WL, Li SQ, Xue L.
    Chin Med J (Engl); 2012 Mar 01; 125(6):1063-7. PubMed ID: 22613532
    [Abstract] [Full Text] [Related]

  • 19. Contrast induced nephropathy in patients with pre-existing renal impairment undergoing coronary angiogram and percutaneous transluminal coronary angioplasty.
    Subedi B, Siddique MA, Zaman SM, Hasan MI, Arzu J, Awal A, Fatema K.
    Mymensingh Med J; 2011 Apr 01; 20(2):270-4. PubMed ID: 21522099
    [Abstract] [Full Text] [Related]

  • 20. Long-term impact of mild chronic kidney disease in patients with acute coronary syndrome undergoing percutaneous coronary interventions.
    Dohi T, Miyauchi K, Okazaki S, Yokoyama T, Tamura H, Kojima T, Yokoyama K, Kurata T, Daida H.
    Nephrol Dial Transplant; 2011 Sep 01; 26(9):2906-11. PubMed ID: 21300704
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.